Pulmonary hypertension (PH) is a pathophysiological disorder that may involve multiple
clinical conditions and may be associated with a variety of cardiovascular and respiratory …

Importance Sarcoidosis is an inflammatory granulomatous disease of unknown cause that
affects an estimated 2 to 160 people per 100 000 worldwide and can involve virtually any …

Background The major reasons to treat sarcoidosis are to lower the morbidity and mortality
risk or to improve quality of life (QoL). The indication for treatment varies depending on …

Guidelines summarize and evaluate available evidence, with the aim of assisting health
professionals in proposing the best management strategies for an individual patient with a …

Sarcoidosis-associated pulmonary hypertension (SAPH) is an important complication of
advanced sarcoidosis. Over the past few years, there have been several studies dealing …

Sarcoidosis is a heterogeneous disease, which can affect virtually every body organ, even
though lungs and intra thoracic lymph nodes are almost universally affected. The presence …

Introduction Pulmonary fibrosing sarcoidosis is associated with increased mortality. This
study was aimed to explore the prognosis value of a panel of parameters for predicting …

The term “advanced sarcoidosis” is used for forms of sarcoidosis with a significant risk of
loss of organ function or death. Advanced sarcoidosis often involves the lung and is …

Pulmonary hypertension (PH) is a disease of pulmonary artery stenosis and blockage
caused by abnormal pulmonary artery smooth muscle cells (PASMCs), with high morbidity …

Sarcoidosis is a systemic granulomatous inflammatory disease of unknown etiology. It
affects the lungs in over 90% of patients yet extra-pulmonary and multi-organ involvement is …